S&P Futures
4,357.50 +20.00 (+0.46%) Dow Futures
34,043.00 +151.00 (+0.45%) Nasdaq Futures
14,960.25 +100.50 (+0.68%) Russell 2000 Futures
1,819.20 +10.10 (+0.56%) Crude Oil
91.74 +0.03 (+0.03%) Gold
1,888.20 +9.60 (+0.51%)
Adaptimmune Therapeutics plc (ADAP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.7652 - 0.8099 |
| 52 Week Range | 0.6800 - 2.6500 |
| Volume | |
| Avg. Volume | 547,604 |
| Market Cap | 177.681M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5200 |
| Earnings Date | Aug 09, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.77 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADAP
Related Research
- Adaptimmune Therapeutics plcXNCR: Lowering target price to $21.00XENCOR INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat2 days agoArgus Research
NewsfileDr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Development. Dr. Chagin will oversee the Company's early-stage pipeline activities from pre-IND and IND activities through Phase 1 clinical trials. Karen joins Adaptimmune from Tmunity where she served as Chief Me
NewsfileAdaptimmune Reports Second Quarter Financial Results and Business Update
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023Transition of lete-cel from GSK and data from the completed pivotal trial in synovial sarcoma and MRCLS expected in late 2023Initiated Phase 2 SURPASS-3 trial in ovarian cancer, which has the potential to be registrational and is supported by RMAT designation Completed strategic combination with TCR2 ...
NewsfileAdaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. EDT (1:00 p.m. BST) that same day.The press ...
